DrugPatentWatch Database Preview
Details for Patent: 7,855,211
Email this page to a colleague
Which drugs does patent 7,855,211 protect, and when does it expire?
Patent 7,855,211 protects VERZENIO and is included in one NDA.
This patent has fifty patent family members in forty-four countries.
Summary for Patent: 7,855,211
| Title: | Protein kinase inhibitors |
| Abstract: | The present invention provides a compound of formula (I): ##STR00001## or a pharmaceutically acceptable salt thereof which is useful in the treatment of cell proliferative diseases. |
| Inventor(s): | Coates; David A (Indianapolis, IN), Gelbert; Lawrence Mark (Indianapolis, IN), Knobeloch; John M. (Indianapolis, IN), De Dios Magana; Alfonso (Carmel, IN), De Prado Gonzalez; Ana (Madrid, ES), Filadelfa Del Prado Catalina; Miriam (Madrid, ES), Garcia Paredes; Maria Cristina (Madrid, ES), Martin De La Nava; Eva Maria (Madrid, ES), Martin Ortega Finger; Maria Dolores (Madrid, ES), Martinez Perez; Jose Antonio (Madrid, ES), Mateo Herranz; Ana Isabel (Madrid, ES), Perez Martinez; Carlos (Madrid, ES), Sanchez Martinez; Concepcion (Madrid, ES) |
| Assignee: | Eli Lilly and Company (Indianapolis, IN) |
| Application Number: | 12/637,789 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Formulation; Compound; |
Recent additions to Drugs Protected by US Patent 7,855,211
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Type | RLD | Patent No. | Product | Substance | Delist Req. | Patent Expiration | Usecode | Patented / Exclusive Use |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Eli Lilly And Co | VERZENIO | abemaciclib | TABLET | 208716 | Sep 28, 2017 | RX | Yes | ⤷ Try it Free | Y | Y | ⤷ Try it Free | U-2132 | IN COMBINATION WITH FULVESTRANT FOR THE TREATMENT OF WOMEN WITH HORMONE RECEPTOR (HR)-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER WITH DISEASE PROGRESSION FOLLOWING ENDOCRINE THERAPY | |
| Eli Lilly And Co | VERZENIO | abemaciclib | TABLET | 208716 | Sep 28, 2017 | RX | Yes | ⤷ Try it Free | Y | Y | ⤷ Try it Free | U-2135 | AS MONOTHERAPY FOR THE TREATMENT OF ADULT PATIENTS WITH HR-POSITIVE, HER2-NEGATIVE ADVANCED OR METASTIC BREAST CANCER WITH DISEASE PROGRESSION FOLLOWING ENDOCRINE THERAPY AND PRIOR CHEMOTHERAPY IN THE METASTATIC SETTING | |
| Eli Lilly And Co | VERZENIO | abemaciclib | TABLET | 208716 | Sep 28, 2017 | RX | Yes | ⤷ Try it Free | Y | Y | ⤷ Try it Free | U-2251 | IN COMBINATION WITH AN AROMATASE INHIBITOR AS INITIAL ENDOCRINE-BASED THERAPY FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR (HR)-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER | |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Type | >RLD | >Patent No. | >Product | >Substance | >Delist Req. | >Patent Expiration | >Usecode | >Patented / Exclusive Use |
Drugs Protected by US Patent 7,855,211
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Eli Lilly And Co | VERZENIO | abemaciclib | TABLET;ORAL | 208716-001 | Sep 28, 2017 | RX | Yes | No | ⤷ Try it Free | ⤷ Try it Free | Y | Y | IN COMBINATION WITH AN AROMATASE INHIBITOR AS INITIAL ENDOCRINE-BASED THERAPY FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR (HR)-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER | ⤷ Try it Free | ||
| Eli Lilly And Co | VERZENIO | abemaciclib | TABLET;ORAL | 208716-001 | Sep 28, 2017 | RX | Yes | No | ⤷ Try it Free | ⤷ Try it Free | Y | Y | IN COMBINATION WITH FULVESTRANT FOR THE TREATMENT OF WOMEN WITH HORMONE RECEPTOR (HR)-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER WITH DISEASE PROGRESSION FOLLOWING ENDOCRINE THERAPY | ⤷ Try it Free | ||
| Eli Lilly And Co | VERZENIO | abemaciclib | TABLET;ORAL | 208716-001 | Sep 28, 2017 | RX | Yes | No | ⤷ Try it Free | ⤷ Try it Free | Y | Y | AS MONOTHERAPY FOR THE TREATMENT OF ADULT PATIENTS WITH HR-POSITIVE, HER2-NEGATIVE ADVANCED OR METASTIC BREAST CANCER WITH DISEASE PROGRESSION FOLLOWING ENDOCRINE THERAPY AND PRIOR CHEMOTHERAPY IN THE METASTATIC SETTING | ⤷ Try it Free | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 7,855,211
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| 08380343 | Dec 22, 2008 | |
International Family Members for US Patent 7,855,211
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 074575 | ⤷ Try it Free | |||
| Australia | 2009330365 | ⤷ Try it Free | |||
| Brazil | PI0924183 | ⤷ Try it Free | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
